

BOND LABORATORIES, INC.  
Form 8-K  
March 09, 2011

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 9 , 2011

Commission File Number: 000-52369

Bond Laboratories, Inc.  
(Exact name of small business issuer as specified in its charter)

Nevada  
(State or other jurisdiction of incorporation or organization)  
20-3464383  
(IRS Employer Identification No.)

11011 Q Street, Building A Suite 106, Omaha, Nebraska 68137  
(Address of principal executive offices)

402-333-5260  
(Registrant's Telephone number)

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

**Item 2.02 Results of Operations and Financial Condition.**

On March 9, 2011, Bond Laboratories, Inc. (the "Company") issued a press release announcing record revenue growth at its NDS Nutrition (TM) division. NDS revenue for the month ended February 28, 2011 increased 46% over the comparable period in 2010 from \$688,000 to over \$1.0 million. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 8.01 Other Events.**

See Item 2.02.

**Item 9.01 Financial Statements and Exhibits.**

See Exhibit Index.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bond Laboratories, Inc.

Date: *March 9, 2011*

By: */s/ Michael Abrams*

---

*Name: Michael Abrams*

*Title: Chief Financial Officer*

---

Exhibit Index

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.1	Bond Labs Mar 9 2011 Press Release